Last updated: July 31, 2026
Losartan potassium and hydrochlorothiazide is an established fixed-dose combination antihypertensive marketed originally as Hyzaar by Merck. The product combines angiotensin II receptor blockade with thiazide diuresis and is approved for hypertension, including patients inadequately controlled on losartan or hydrochlorothiazide alone. The product is fully genericized in the United States, has no material remaining market exclusivity, and faces low regulatory and patent barriers. Future commercial growth will depend on hypertension prevalence, generic volume, combination-pill adoption, and price competition rather than clinical differentiation.
What is losartan potassium and hydrochlorothiazide approved to treat?
The combination contains losartan potassium, an angiotensin II receptor blocker, and hydrochlorothiazide, a thiazide diuretic. U.S. strengths generally include:
| Strength |
Losartan potassium |
Hydrochlorothiazide |
| Low dose |
50 mg |
12.5 mg |
| Standard high dose |
100 mg |
12.5 mg |
| Higher diuretic dose |
100 mg |
25 mg |
The FDA-approved indication is hypertension. The combination may be used when blood pressure is not adequately controlled with monotherapy or when a patient is already receiving the individual components at equivalent doses. It is not approved for uncomplicated first-line use in every patient, although fixed-dose therapy is widely used when combination treatment is clinically appropriate.[1]
Losartan blocks the AT1 receptor and reduces vasoconstriction and aldosterone-mediated sodium retention. Hydrochlorothiazide increases renal sodium and water excretion. The two mechanisms produce additive blood-pressure reduction.
What are the principal clinical risks?
Key label warnings include:
- Fetal toxicity and contraindication during pregnancy.
- Hyperkalemia, particularly in patients with renal impairment or diabetes.
- Hypotension and acute kidney injury in volume-depleted patients.
- Electrolyte abnormalities, including hyponatremia, hypokalemia and hypomagnesemia.
- Hyperuricemia and potential worsening of gout.
- Photosensitivity and non-melanoma skin-cancer risk associated with hydrochlorothiazide exposure.
- Reduced antihypertensive effect and renal risk with chronic nonsteroidal anti-inflammatory drug use.
- Lithium toxicity when lithium is coadministered.
The combination requires monitoring of blood pressure, renal function, potassium, sodium and other electrolytes. The hydrochlorothiazide component also creates a long-term safety distinction from losartan monotherapy.
What is the current clinical-trial status of losartan hydrochlorothiazide?
Losartan hydrochlorothiazide is a mature product with no major active development program for a new indication. Clinical research has shifted from registration trials to comparative effectiveness, adherence, cardiovascular outcomes, real-world utilization and combination-treatment strategies.
What did the pivotal trials establish?
The original development program established that losartan plus hydrochlorothiazide lowered blood pressure more effectively than either component alone in patients requiring combination therapy. The product’s clinical rationale rests on complementary mechanisms rather than a novel pharmacologic target.
Losartan also has a separate evidence base in hypertension, left ventricular hypertrophy and diabetic nephropathy. The LIFE study showed lower cardiovascular morbidity and mortality with losartan-based therapy than atenolol-based therapy in patients with hypertension and left ventricular hypertrophy, despite similar blood-pressure control.[2] The RENAAL study evaluated losartan in type 2 diabetes with nephropathy and demonstrated renal benefits, but it did not establish the fixed-dose combination as a treatment for diabetic nephropathy.[3]
Are new Phase 3 trials expected?
No major Phase 3 program is required for the approved fixed-dose combination. New trials would be commercially difficult to justify because:
- The active ingredients are off patent.
- Generic products are widely available.
- Blood-pressure efficacy is well established.
- The FDA does not require new outcome trials for each generic manufacturer.
- Incremental clinical differentiation is limited.
Potential future research areas include adherence, single-pill combination use, resistant hypertension, chronic kidney disease subgroups and comparative effectiveness against other ARB/thiazide combinations. These studies are more likely to generate health-economic or guideline evidence than a new regulatory approval.
What does the clinical-trial pipeline show?
ClinicalTrials.gov contains extensive historical research involving losartan and hydrochlorothiazide, but the majority of active innovation in hypertension is concentrated in other areas:
- Mineralocorticoid receptor antagonists.
- Renin inhibitors and novel renal mechanisms.
- Dual and triple fixed-dose combinations.
- Device-supported hypertension management.
- Resistant-hypertension therapies.
- Cardiovascular and kidney-risk reduction using SGLT2 inhibitors and related agents.
Losartan hydrochlorothiazide remains a comparator or background therapy in some hypertension and renal studies rather than a primary investigational product.[4]
What is the FDA and Orange Book status?
Hyzaar was approved by the FDA in 1995 under NDA 020386. The FDA-approved product is supplied by Merck, while numerous companies market therapeutically equivalent generic versions.[1]
| Regulatory issue |
Status |
| Original brand |
Hyzaar |
| Original sponsor |
Merck |
| FDA approval |
1995 |
| Dosage form |
Oral tablets |
| Prescription status |
Prescription-only |
| Generic availability |
Extensive |
| Reference product exclusivity |
Expired |
| Orange Book relevance |
Historical listed patents and current reference-product entry |
| Biosimilar pathway |
Not applicable |
The product is a small-molecule oral drug, not a biologic. Biosimilar substitution rules therefore do not apply. Generic applicants generally use the abbreviated new drug application pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than repeat the full clinical-development program.
What is the Orange Book status of Hyzaar?
Hyzaar’s historical Orange Book patent protection has expired. The product does not have a commercially meaningful period of remaining U.S. market exclusivity. Current competitive protection depends on manufacturing cost, supply reliability, distribution contracts and formulary positioning.
The FDA Orange Book remains the relevant source for checking the reference product, approved strengths and any current listed patent or exclusivity entry. Patent records and Orange Book listings should be reviewed together because a historical patent may have expired, been delisted or have no practical effect on generic entry.[5]
What patents protect losartan hydrochlorothiazide?
The principal original losartan patents were filed in the 1980s and early 1990s and have expired. The key losartan compound patent was U.S. Patent No. 5,138,069, assigned to E.I. du Pont de Nemours and later associated with Merck’s Cozaar franchise. Its U.S. term expired in 2010, subject to applicable patent-term adjustments and regulatory exclusivity calculations.[6]
Historical combination and formulation patents included patents directed to pharmaceutical compositions containing losartan and hydrochlorothiazide. U.S. Patent No. 5,608,075 is commonly associated with the combination product and had a term extending into the mid-2010s. That protection has also expired.[7]
| Patent category |
Representative protection |
Current position |
| Losartan compound |
U.S. Patent No. 5,138,069 |
Expired |
| Losartan/HCTZ combination |
U.S. Patent No. 5,608,075 |
Expired |
| Tablet formulation |
Historical formulation patents |
Expired or commercially immaterial |
| Method of use |
Hypertension-related claims |
Expired or not a material barrier |
| Manufacturing process |
Process patents and know-how |
No broad blocking barrier identified for generic entry |
Are formulation or method-of-use patents still a barrier?
No material blocking formulation or method-of-use patent is expected to prevent ordinary generic entry in the United States. Generic manufacturers may use different excipients, manufacturing processes or tablet presentations if they meet FDA bioequivalence and quality requirements.
Manufacturing know-how can still affect product quality. Relevant technical issues include:
- Uniform distribution of low-dose hydrochlorothiazide.
- Control of tablet dissolution.
- Stability of losartan under humidity and temperature stress.
- Control of impurities and degradation products.
- Reliable supply of active pharmaceutical ingredients.
- Packaging that protects tablet stability.
These are operational barriers, not exclusivity barriers.
When does losartan hydrochlorothiazide lose exclusivity?
Losartan hydrochlorothiazide lost meaningful U.S. exclusivity years ago. The compound and combination patents expired before or during the 2010s, and generic manufacturers entered the market. No remaining regulatory exclusivity is expected to restrict ordinary ANDA competition.
The commercial timeline is:
| Period |
Event |
| 1995 |
FDA approval of Hyzaar |
| 2000s |
Expansion of losartan and combination-product use |
| 2010 |
Expiration of core losartan compound patent |
| Mid-2010s |
Expiration of key combination-related protection |
| 2010s onward |
Broad generic competition |
| 2020s |
Mature, low-price generic market |
Which companies compete in the market?
Competition is fragmented. Depending on country and procurement channel, suppliers can include:
- Merck, through the Hyzaar reference product.
- Teva Pharmaceuticals.
- Sandoz.
- Viatris and legacy Mylan operations.
- Lupin.
- Torrent Pharmaceuticals.
- Zydus Lifesciences.
- Dr. Reddy’s Laboratories.
- Cipla.
- Sun Pharma.
- Hikma and regional generic suppliers.
The supplier set differs by jurisdiction, strength and tender. Retail-market share is often determined by pharmacy benefit contracts and wholesaler availability. Hospital and government channels are more sensitive to tender pricing, supply continuity and manufacturing-site qualification.
What is the market size and forecast for losartan hydrochlorothiazide?
Losartan hydrochlorothiazide is a mature generic category with high unit demand but low average selling prices. Public market-research estimates vary because some reports count only the fixed-dose combination, while others combine it with losartan monotherapy or the wider ARB/thiazide market.
A reasonable commercial framework is:
| Metric |
2024-2025 assessment |
2030 projection |
| Market stage |
Mature generic |
Mature generic |
| Volume growth |
Low single digit |
Low to mid single digit |
| Price trend |
Flat to declining |
Continued price pressure |
| Revenue growth |
Flat or modest |
Low single digit |
| Main demand driver |
Hypertension prevalence |
Aging and chronic treatment |
| Main risk |
Generic price erosion |
Substitution by newer combinations |
| Innovation level |
Low |
Low |
A global fixed-dose losartan/hydrochlorothiazide market estimate in the broad range of roughly $0.8 billion to $1.5 billion annually is plausible when retail, institutional and regional generic sales are combined. The range reflects inconsistent market definitions and the inclusion or exclusion of related losartan products. A base-case projection is approximately 1% to 3% annual revenue growth through 2030, with volume growth partly offset by price erosion.
The broader hypertension market is much larger. Losartan hydrochlorothiazide competes with:
- Valsartan/hydrochlorothiazide.
- Irbesartan/hydrochlorothiazide.
- Telmisartan/hydrochlorothiazide.
- Olmesartan/hydrochlorothiazide.
- Amlodipine/ARB combinations.
- Single-pill triple therapies.
What drives demand?
Demand is supported by:
- Rising hypertension prevalence.
- Growth in treated older populations.
- Guideline support for combination therapy when blood pressure is substantially above target.
- Better adherence with single-pill products.
- Low generic prices.
- Availability across retail and public-health channels.
Demand is constrained by:
- Substitution to other ARBs.
- Use of calcium-channel-blocker combinations.
- Concerns about thiazide-related electrolyte and metabolic effects.
- Fixed-dose inflexibility when individual component titration is needed.
- Generic contracting that favors the lowest-cost supplier.
How does losartan hydrochlorothiazide compare with competing combinations?
| Combination |
Competitive position |
Differentiating consideration |
| Losartan/HCTZ |
Low-cost, established |
Long clinical history and broad generic supply |
| Valsartan/HCTZ |
Strong ARB competitor |
Extensive cardiovascular familiarity |
| Irbesartan/HCTZ |
Established |
Frequent use in diabetes and kidney-risk populations |
| Telmisartan/HCTZ |
Long half-life |
Attractive once-daily pharmacology |
| Olmesartan/HCTZ |
Potent blood-pressure reduction |
Gastrointestinal safety considerations for olmesartan |
| ARB/amlodipine |
Strong commercial alternative |
Avoids thiazide-related electrolyte effects |
| ARB/indapamide |
Regional competitor |
Different diuretic profile and availability |
Losartan hydrochlorothiazide is most competitive where price, familiarity and generic availability outweigh differentiation. It is less advantaged in premium markets where physicians prefer longer-acting ARBs, calcium-channel-blocker combinations or therapies with stronger kidney and cardiovascular positioning.
What generic-entry risks exist?
Patent-based generic-entry risk is minimal because the core rights have expired. Commercial risks remain:
- Abrupt API shortages.
- FDA manufacturing observations.
- Product recalls.
- Dissolution or content-uniformity failures.
- Price competition that compresses margins.
- Consolidation among generic suppliers.
- State and federal contracting changes.
- Substitution by newer fixed-dose combinations.
A new entrant would face low legal risk but high execution risk. The most defensible commercial strategy would involve dependable supply, efficient manufacturing, multiple strengths, and distribution access rather than new intellectual property.
Are there licensing deals or settlement agreements?
The major commercial history is based on Merck’s internal development and subsequent generic competition. There is no widely recognized current licensing arrangement that preserves exclusivity for the losartan/hydrochlorothiazide combination. Any historical Paragraph IV settlements involving specific ANDA applicants would have been overtaken by patent expiry and broad market entry.
Paragraph IV litigation was relevant during the period when generic applicants challenged listed patents. It is no longer a meaningful barrier to market access for standard strengths because the principal patents have expired.
What is the investment outlook?
The product has limited upside as an innovation asset. Its value is concentrated in dependable generic cash flow, portfolio scale and manufacturing efficiency.
| Investment factor |
Assessment |
| Patent strength |
Low; core protection expired |
| Regulatory barrier |
Low to moderate |
| Clinical differentiation |
Low |
| Demand stability |
High |
| Pricing power |
Low |
| Supply-chain sensitivity |
Moderate to high |
| Litigation exposure |
Low on core patents |
| Revenue durability |
Moderate |
| Probability of major new indication |
Low |
Revenue exposure is more meaningful for manufacturers with broad hypertension portfolios than for a company relying on this product alone. The combination can support portfolio retention, pharmacy relationships and manufacturing utilization, but it is unlikely to generate premium pricing or substantial licensing value.
Key Takeaways
- Losartan potassium/hydrochlorothiazide is an FDA-approved fixed-dose treatment for hypertension.
- Hyzaar was approved in 1995 and is now widely genericized.
- Core losartan and combination patents, including U.S. Patent Nos. 5,138,069 and 5,608,075, have expired.
- No biosimilar pathway applies because the product is a small-molecule drug.
- No major new Phase 3 development program is expected.
- Clinical research is focused on adherence, comparative effectiveness and broader hypertension treatment strategies.
- Market demand should remain stable, but price erosion will limit revenue growth.
- A reasonable base case is low single-digit annual revenue growth through 2030.
- The principal barriers are manufacturing quality, supply reliability and contracting, not patent rights.
- The product has stable generic demand but limited innovation or exclusivity value.
Frequently Asked Questions
Is losartan hydrochlorothiazide the same as Hyzaar?
Yes. Hyzaar is the original Merck brand for the fixed-dose combination of losartan potassium and hydrochlorothiazide. Multiple generic versions are available.
Can generic manufacturers launch losartan hydrochlorothiazide without a license from Merck?
Yes. Expiration of the relevant patent protection allows qualified manufacturers to market approved generic products without a continuing license from Merck.
Does losartan hydrochlorothiazide have pediatric exclusivity?
No current pediatric exclusivity period materially affects the generic market. Any historical regulatory exclusivity associated with the original approval has expired.
Is losartan hydrochlorothiazide protected by a new formulation patent?
No commercially significant blocking formulation patent is generally associated with the mature U.S. generic market. Individual manufacturers may hold process or formulation rights, but those rights do not ordinarily prevent alternative generic products.
Will losartan hydrochlorothiazide sales increase through 2030?
Unit demand is likely to remain stable or grow modestly because hypertension prevalence is increasing. Revenue growth should remain limited by generic price competition and substitution by other ARB combinations.
References
- U.S. Food and Drug Administration. (2024). Hyzaar prescribing information. FDA.
- Dahlof, B., Devereux, R. B., Kjeldsen, S. E., et al. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study. The Lancet, 359(9311), 995-1003.
- Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine, 345(12), 861-869.
- National Library of Medicine. (2024). ClinicalTrials.gov: Losartan and hydrochlorothiazide clinical studies.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Patent No. 5,138,069. (1992). Imidazole-5-carboxylic acids and derivatives thereof.
- U.S. Patent No. 5,608,075. (1997). Pharmaceutical compositions containing losartan and a diuretic.
